Thyroid hormone reduces PCSK9 and stimulates bile acid synthesis in humans

Journal of Lipid Research

Volumn 55, Issue 11, 2014, Pages 2408-2415

  Bonde, Ylva ^a   Breuer, Olof ^b   Lütjohann, Dieter ^c   Sjöberg, Stefan ^a   Angelin, Bo ^a   Rudling, Mats ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b Karo Bio   (Sweden)

^c UNIVERSITY HOSPITAL BONN   (Germany)

Author keywords

Bile acids and salts biosynthesis; Cholesterol 7alpha hydroxylase; Cholesterol absorption; Drug therapy hypolipidemic drugs; Eprotirome; Fibroblast growth factor; Fibroblast growth factor 19; Fibroblast growth factor 21; Lipoproteins metabolism; Proprotein convertase subtilisin kexin type 9

Indexed keywords

APOLIPOPROTEIN B; BILE ACID; DNA BINDING PROTEIN; EPROTIROME; FIBROBLAST GROWTH FACTOR 19; FIBROBLAST GROWTH FACTOR 21; LIPOPROTEIN; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9 PROTEIN; THYROID HORMONE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; 3-((3,5-DIBROMO-4-(4-HYDROXY-3-(1-METHYLETHYL)PHENOXY)PHENYL)AMINO)-3-OXOPROPANOIC ACID; ANILIDE; CHOLESTEROL; FGF9 PROTEIN, HUMAN; FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 9; GLUCOSE BLOOD LEVEL; INSULIN; PCSK9 PROTEIN, HUMAN; SERINE PROTEINASE; THYROID HORMONE RECEPTOR;

ABSORPTION; ADULT; AGED; ARTICLE; BILE ACID SYNTHESIS; BODY COMPOSITION; CHOLESTEROL METABOLISM; CHOLESTEROL SYNTHESIS; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HORMONE ACTION; HUMAN; HYPERTHYROIDISM; LIPOLYSIS; MALE; TRIACYLGLYCEROL BLOOD LEVEL; ADOLESCENT; AGONISTS; BIOSYNTHESIS; BLOOD; CHEMISTRY; CLINICAL TRIAL; DRUG EFFECTS; ENZYMOLOGY; GLUCOSE BLOOD LEVEL; INTESTINE ABSORPTION; LIVER; METABOLISM; MIDDLE AGED; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANILIDES; APOLIPOPROTEINS B; BILE ACIDS AND SALTS; BLOOD GLUCOSE; BODY COMPOSITION; CHOLESTEROL; FEMALE; FIBROBLAST GROWTH FACTOR 9; FIBROBLAST GROWTH FACTORS; HUMANS; HYPERTHYROIDISM; INSULIN; INTESTINAL ABSORPTION; LIPOPROTEIN(A); LIVER; MALE; MIDDLE AGED; PROPROTEIN CONVERTASES; RECEPTORS, THYROID HORMONE; SERINE ENDOPEPTIDASES; THYROID HORMONES; YOUNG ADULT;

EID: 84912002789     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.M051664     Document Type: Article

References (53)

1. Yen, P. M. 2001. Physiological and molecular basis of thyroid hormone action. Physiol. Rev. 81: 1097-1142.
2. Zhang, J., and M. A. Lazar. 2000. The mechanism of action of thyroid hormones. Annu. Rev. Physiol. 62: 439-466.
3. Song, Y., X. Yao, and H. Ying. 2011. Thyroid hormone action in metabolic regulation. Protein Cell. 2: 358-368.
4. Roberts, C. G., and P. W. Ladenson. 2004. Hypothyroidism. Lancet. 363: 793-803.
5. Ness, G. C., L. C. Pendleton, Y. C. Li, and J. Y. Chiang. 1990. Effect of thyroid hormone on hepatic cholesterol 7 alpha hydroxylase, LDL receptor, HMG-CoA reductase, farnesyl pyrophosphate synthetase and apolipoprotein A-I mRNA levels in hypophysectomized rats. Biochem. Biophys. Res. Commun. 172: 1150-1156.
6. Bonde, Y., T. Plosch, F. Kuipers, B. Angelin, and M. Rudling. 2012. Stimulation of murine biliary cholesterol secretion by thyroid hormone is dependent on a functional ABCG5/G8 complex. Hepatology. 56: 1828-1837.
7. Gälman, C., Y. Bonde, M. Matasconi, B. Angelin, and M. Rudling. 2008. Dramatically increased intestinal absorption of cholesterol following hypophysectomy is normalized by thyroid hormone. Gastroenterology. 134: 1127-1136.
8. Lambert, G., B. Sjouke, B. Choque, J. J. Kastelein, and G. K. Hovingh. 2012. The PCSK9 decade. J. Lipid Res. 53: 2515-2524.
9. Angelin, B., T. E. Larsson, and M. Rudling. 2012. Circulating fibroblast growth factors as metabolic regulators - a critical appraisal. Cell Metab. 16: 693-705.
10. Berkenstam, A., J. Kristensen, K. Mellstrom, B. Carlsson, J. Malm, S. Rehnmark, N. Garg, C. M. Andersson, M. Rudling, F. Sjoberg, et al. 2008. The thyroid hormone mimetic compound KB2115 lowers plasma LDL cholesterol and stimulates bile acid synthesis without cardiac effects in humans. Proc. Natl. Acad. Sci. USA. 105: 663-667.
11. Ladenson, P. W., J. D. Kristensen, E. C. Ridgway, A. G. Olsson, B. Carlsson, I. Klein, J. D. Baxter, and B. Angelin. 2010. Use of the thyroid hormone analogue eprotirome in statin-treated dyslipidemia. N. Engl. J. Med. 362: 906-916.
12. Angelin, B., J. D. Kristensen, M. Eriksson, B. Carlsson, I. Klein, A. G. Olsson, E. Chester Ridgway, and P. W. Ladenson. 2014. Reductions in serum levels of LDL cholesterol, apolipoprotein B, triglycerides and lipoprotein(a) in hypercholesterolaemic patients treated with the liver-selective thyroid hormone receptor agonist eprotirome. J. Intern. Med. Epub ahead of print. April 22, 2014; doi: 10.1111/joim.12261.
13. Parini, P., L. Johansson, A. Broijersen, B. Angelin, and M. Rudling. 2006. Lipoprotein profiles in plasma and interstitial fluid analyzed with an automated gel-filtration system. Eur. J. Clin. Invest. 36: 98-104.
14. Gälman, C., I. Arvidsson, B. Angelin, and M. Rudling. 2003. Monitoring hepatic cholesterol 7alpha-hydroxylase activity by assay of the stable bile acid intermediate 7alpha-hydroxy-4-cholesten-3-one in peripheral blood. J. Lipid Res. 44: 859-866.
15. Axelson, M., I. Bjorkhem, E. Reihner, and K. Einarsson. 1991. The plasma level of 7 alpha-hydroxy-4-cholesten-3-one reflects the activity of hepatic cholesterol 7 alpha-hydroxylase in man. FEBS Lett. 284: 216-218.
16. Axelson, M., A. Aly, and J. Sjovall. 1988. Levels of 7 alpha-hydroxy-4-cholesten-3-one in plasma reflect rates of bile acid synthesis in man. FEBS Lett. 239: 324-328.
17. Sauter, G., F. Berr, U. Beuers, S. Fischer, and G. Paumgartner. 1996. Serum concentrations of 7alpha-hydroxy-4-cholesten-3-one reflect bile acid synthesis in humans. Hepatology. 24: 123-126.
18. Gälman, C., B. Angelin, and M. Rudling. 2005. Bile acid synthesis in humans has a rapid diurnal variation that is asynchronous with cholesterol synthesis. Gastroenterology. 129: 1445-1453.
19. Björkhem, I., E. Reihner, B. Angelin, S. Ewerth, J. E. Akerlund, and K. Einarsson. 1987. On the possible use of the serum level of 7 alpha-hydroxycholesterol as a marker for increased activity of the cholesterol 7 alpha-hydroxylase in humans. J. Lipid Res. 28: 889-894.
20. Knabe, C., T. Sudhop, K. von Bergmann, and D. Lutjohann. 2007. Degradation of 24S-hydroxycholesterol in men is not regulated by CYP7A1. Int. J. Clin. Pharmacol. Ther. 45: 577-582.
21. Lund, E., L. Sisfontes, E. Reihner, and I. Bjorkhem. 1989. Determination of serum levels of unesterified lathosterol by isotope dilution-mass spectrometry. Scand. J. Clin. Lab. Invest. 49: 165-171.
22. Kempen, H. J., J. F. Glatz, J. A. Gevers Leuven, H. A. van der Voort, and M. B. Katan. 1988. Serum lathosterol concentration is an indicator of whole-body cholesterol synthesis in humans. J. Lipid Res. 29: 1149-1155.
23. Miettinen, T. A., R. S. Tilvis, and Y. A. Kesaniemi. 1990. Serum plant sterols and cholesterol precursors reflect cholesterol absorption and synthesis in volunteers of a randomly selected male population. Am. J. Epidemiol. 131: 20-31.
24. Björkhem, I., T. Miettinen, E. Reihner, S. Ewerth, B. Angelin, and K. Einarsson. 1987. Correlation between serum levels of some cholesterol precursors and activity of HMG-CoA reductase in human liver. J. Lipid Res. 28: 1137-1143.
25. Lütjohann, D., M. Stroick, T. Bertsch, S. Kühl, B. Lindenthal, K. Thelen, U. Andersson, I. Björkhem, K. von Bergmann, and K. Fassbender. 2004. High doses of simvastatin, pravastatin, and cholesterol reduce brain cholesterol synthesis in guinea pigs. Steroids. 69: 431-438.
26. Thelen, K. M., K. M. Rentsch, U. Gutteck, M. Heverin, M. Olin, U. Andersson, A. von Eckardstein, I. Bjorkhem, and D. Lutjohann. 2006. Brain cholesterol synthesis in mice is affected by high dose of simvastatin but not of pravastatin. J. Pharmacol. Exp. Ther. 316: 1146-1152.
27. Lütjohann, D., C. Hahn, W. Prange, T. Sudhop, M. Axelson, T. Sauerbruch, K. von Bergmann, and C. Reichel. 2004. Influence of rifampin on serum markers of cholesterol and bile acid synthesis in men. Int. J. Clin. Pharmacol. Ther. 42: 307-313.
28. Tavori, H., D. Fan, J. L. Blakemore, P. G. Yancey, L. Ding, M. F. Linton, and S. Fazio. 2013. Serum proprotein convertase subtilisin/kexin type 9 and cell surface low-density lipoprotein receptor: evidence for a reciprocal regulation. Circulation. 127: 2403-2413.
29. Lakoski, S. G., T. A. Lagace, J. C. Cohen, J. D. Horton, and H. H. Hobbs. 2009. Genetic and metabolic determinants of plasma PCSK9 levels. J. Clin. Endocrinol. Metab. 94: 2537-2543.
30. Green, P. H., R. M. Glickman, J. W. Riley, and E. Quinet. 1980. Human apolipoprotein A-IV. Intestinal origin and distribution in plasma. J. Clin. Invest. 65: 911-919.
31. Adams, A. C., I. Astapova, F. M. Fisher, M. K. Badman, K. E. Kurgansky, J. S. Flier, A. N. Hollenberg, and E. Maratos-Flier. 2010. Thyroid hormone regulates hepatic expression of fibroblast growth factor 21 in a pparalpha-dependent manner. J. Biol. Chem. 285: 14078-14082.
32. Gullberg, H., M. Rudling, D. Forrest, B. Angelin, and B. Vennstrom. 2000. Thyroid hormone receptor beta-deficient mice show complete loss of the normal cholesterol 7alpha-hydroxylase (CYP7A) response to thyroid hormone but display enhanced resistance to dietary cholesterol. Mol. Endocrinol. 14: 1739-1749.
33. Abrams, J. J., and S. M. Grundy. 1981. Cholesterol metabolism in hypothyroidism and hyperthyroidism in man. J. Lipid Res. 22: 323-338.
34. Angelin, B., K. Einarsson, and B. Leijd. 1983. Bile acid metabolism in hypothyroid subjects: response to substitution therapy. Eur. J. Clin. Invest. 13: 99-106.
35. Pauletzki, J., F. Stellaard, and G. Paumgartner. 1989. Bile acid metabolism in human hyperthyroidism. Hepatology. 9: 852-855.
36. Sample, C. E., L. C. Pendleton, and G. C. Ness. 1987. Regulation of 3-hydroxy-3-methylglutaryl coenzyme a reductase mRNA levels by L-triiodothyronine. Biochemistry. 26: 727-731.
37. Gordon, J. I., C. L. Bisgaier, H. F. Sims, O. P. Sachdev, R. M. Glickman, and A. W. Strauss. 1984. Biosynthesis of human preapolipoprotein A-IV. J. Biol. Chem. 259: 468-474.
38. Angelin, B., and M. Rudling. 2010. Lipid lowering with thyroid hormone and thyromimetics. Curr. Opin. Lipidol. 21: 499-506.
39. Packard, C. J., J. Shepherd, G. M. Lindsay, A. Gaw, and M. R. Taskinen. 1993. Thyroid replacement therapy and its influence on postheparin plasma lipases and apolipoprotein-B metabolism in hypothyroidism. J. Clin. Endocrinol. Metab. 76: 1209-1216.
40. Chernogubova, E., R. Strawbridge, H. Mahdessian, A. Malarstig, S. Krapivner, B. Gigante, M. L. Hellenius, U. de Faire, A. Franco-Cereceda, A. C. Syvanen, et al. 2012. Common and low-frequency genetic variants in the PCSK9 locus influence circulating PCSK9 levels. Arterioscler. Thromb. Vasc. Biol. 32: 1526-1534.
41. Persson, L., G. Cao, L. Stahle, B. G. Sjoberg, J. S. Troutt, R. J. Konrad, C. Galman, H. Wallen, M. Eriksson, I. Hafstrom, et al. 2010. Circulating proprotein convertase subtilisin kexin type 9 has a diurnal rhythm synchronous with cholesterol synthesis and is reduced by fasting in humans. Arterioscler. Thromb. Vasc. Biol. 30: 2666-2672.
42. Kronenberg, F., and G. Utermann. 2013. Lipoprotein(a): resurrected by genetics. J. Intern. Med. 273: 6-30.
43. Desai, N. R., P. Kohli, R. P. Giugliano, M. L. O'Donoghue, R. Somaratne, J. Zhou, E. B. Hoffman, F. Huang, W. J. Rogers, S. M. Wasserman, et al. 2013. AMG145, a monoclonal antibody against proprotein convertase subtilisin kexin type 9, significantly reduces lipoprotein(a) in hypercholesterolemic patients receiving statin therapy: an analysis from the LDL-C Assessment with Proprotein Convertase Subtilisin Kexin Type 9 Monoclonal Antibody Inhibition Combined with Statin Therapy (LAPLACE)-Thrombolysis in Myocardial Infarction (TIMI) 57 trial. Circulation. 128: 962-969.
44. Ness, G. C., L. C. Pendelton, and Z. Zhao. 1994. Thyroid hormone rapidly increases cholesterol 7 alpha-hydroxylase mRNA levels in hypophysectomized rats. Biochim. Biophys. Acta. 1214: 229-233.
45. Johansson, L., M. Rudling, T. S. Scanlan, T. Lundasen, P. Webb, J. Baxter, B. Angelin, and P. Parini. 2005. Selective thyroid receptor modulation by GC-1 reduces serum lipids and stimulates steps of reverse cholesterol transport in euthyroid mice. Proc. Natl. Acad. Sci. USA. 102: 10297-10302.
46. Sauter, G., M. Weiss, and R. Hoermann. 1997. Cholesterol 7 alpha-hydroxylase activity in hypothyroidism and hyperthyroidism in humans. Horm. Metab. Res. 29: 176-179.
47. Russell, D. W. 2009. Fifty years of advances in bile acid synthesis and metabolism. J. Lipid Res. 50 (Suppl.): S120-S125.
48. Hellstrom, K., and J. Sjovall. 1961. Conjugation of bile acids in patients with hypothyroidism (bile acids and steroids, 105). J. Atheroscler. Res. 1: 205-210.
49. Lunda˚sen, T., C. Gälman, B. Angelin, and M. Rudling. 2006. Circulating intestinal fibroblast growth factor 19 has a pronounced diurnal variation and modulates hepatic bile acid synthesis in man. J. Intern. Med. 260: 530-536.
50. Yu, H., F. Xia, K. S. Lam, Y. Wang, Y. Bao, J. Zhang, Y. Gu, P. Zhou, J. Lu, W. Jia, et al. 2011. Circadian rhythm of circulating fibroblast growth factor 21 is related to diurnal changes in fatty acids in humans. Clin. Chem. 57: 691-700.
51. Catapano, A. L., Z. Reiner, G. De Backer, I. Graham, M. R. Taskinen, O. Wiklund, S. Agewall, E. Alegria, M. Chapman, P. Durrington, et al. 2011. ESC/EAS guidelines for the management of dyslipidaemias: the task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Atherosclerosis. 217: 3-46.
52. Tancevski, I., E. Demetz, and P. Eller. 2011. Sobetirome: a selective thyromimetic for the treatment of dyslipidemia. Recent Pat Cardiovasc. Drug Discov. 6: 16-19.
53. Tancevski, I., A. Wehinger, E. Demetz, J. Hoefer, P. Eller, E. Huber, U. Stanzl, K. Duwensee, K. Auer, W. Schgoer, et al. 2009. The thyromimetic t-0681 protects from atherosclerosis. J. Lipid Res. 50: 938-944.